Soy protein with and without isoflavones fails to substantially increase postprandial antioxidant capacity

Karrie M. Heneman\textsuperscript{a}, Hebron C. Chang\textsuperscript{b}, Ronald L. Prior\textsuperscript{b}, Francene M. Steinberg\textsuperscript{a,}\textsuperscript{*}

\textsuperscript{a}Department of Nutrition, University of California, Davis, CA 95616-8669, USA
\textsuperscript{b}US Department of Agriculture, Agriculture Research Service, Arkansas Children’s Nutrition Center, Little Rock, AR 72202, USA

Received 3 November 2005; received in revised form 2 March 2006; accepted 6 March 2006

Abstract

Five methods for the assessment of antioxidant capacity [whole plasma conjugated diene formation, low-density lipoprotein oxidation susceptibility, ferric-reducing ability of plasma, oxygen radical absorbance capacity and perchloric-acid-treated oxygen radical absorbance capacity (PCA-ORAC)] were used in a randomized, double-blind, cross-over study to determine the acute postprandial antioxidant protection imparted by the isoflavone component of soy. On separate days, 16 subjects consumed one of three isocaloric shakes containing 25g of protein in the form of soy, with 107 mg of total aglycone units of isoflavones, soy with trace isoflavones (<4 mg) or total milk protein. Blood was collected at baseline, 4h, 6h, and 8h after consumption. Antioxidant capacity, serum isoflavone levels, fat-soluble antioxidants and plasma vitamin C levels were evaluated. Repeated measures analysis of variance showed no significant differences (\(P=.05\)) within treatments over time in four of five antioxidant capacity measurements. Significant differences over time between the soy with trace isoflavones and the total milk protein group were observed using the PCA-ORAC assay. It can be concluded that, on an acute basis, a significant increase in serum antioxidant capacity is not detectable following consumption of soy protein.

\(\textcopyright\) 2007 Elsevier Inc. All rights reserved.

Keywords: Soy protein; Isoflavones; Antioxidant capacity

1. Introduction

Epidemiological evidence suggests that eastern populations that regularly consume soy have a low relative risk of cardiovascular disease (CVD) and have favorable levels of some chronic disease biomarkers, such as low-density lipoprotein (LDL) and total cholesterol \([1–6]\). Although many lifestyle factors may contribute to this association, consumption of soy is one dietary component that has the potential to modulate CVD risk. Controversy exists regarding the contribution of soy foods and bioactive components to the reduction of chronic disease risk factors. Randomized controlled trials have produced inconsistent results, which vary from null to moderately robust protective effects. Despite extensive research, the exact mechanisms for the cardioprotective effect of soy have yet to be confirmed. Soy protein components must be present for lipid-lowering effects to be observed, whereas other biologic effects may be related to isoflavones and their metabolites. The mild hypcholesterolemic effect observed with consumption of soy protein is dependent on the degree of hypercholesterolemia in at-risk individuals \([7–13]\). The shift of LDL particle size to a larger, less atherogenic pattern as a result of soy protein consumption \([13]\) and improvement in endothelial function independent of lipoprotein changes represent two other potential soy-mediated protective mechanisms \([9,14]\).

Soy protein, the soy-derived isoflavones genistein and daidzein, and the metabolite equol are hypothesized to impart antioxidant protection contributing to reduction in oxidative stress and CVD risk. In vitro investigations have demonstrated the hydrogen-donating abilities of isoflavones and metabolites, inhibition of lipid peroxidation and the ability to interact with the oxidants hypochlorous acid and peroxynitrite \([15–18]\). Cell culture studies suggest that they may act by enhancing the cellular antioxidant network by increasing metallothionein mRNA levels \([19]\), inhibiting peroxynitrite-mediated LDL oxidation by delaying tyrosine nitration \([20]\), activating glutathione peroxidase \([21]\) (thereby increasing levels of cellular reduced glutathione) \([22]\) or inhibiting...
superoxide production and, thus, cell-mediated LDL modification [23].

However, clinical trials investigating the antioxidant hypothesis have failed to observe the protective effects of purified isoflavones [24,25], while studies using soy protein preparations have yielded results both supporting [8,26,27] and disproving [14,28,29] the antioxidant cardioprotective theories of soy and its components. A very recent study reported a small significant increase in plasma antioxidant status, yet without much effect on biomarkers of oxidative stress [30]. Hypotheses for these apparent contradictions include differences in study design; soy preparation [31]; the existence of active components other than isoflavones in the protein itself [32]; variations in the ability of study populations to produce equol, a metabolite with potent antioxidant capabilities [33]; and the possibility that there is no clinical significance to the minor changes observed in some reports. These studies have provided partial explanations for literature discrepancies; however, questions regarding the antioxidant potential of soy and its in vivo components at physiologic doses still remain.

A question yet to be investigated is whether isoflavones act as acute antioxidants during the postprandial period corresponding to circulating peak plasma levels. It is possible that the postprandial antioxidant effects of soy consumption are subtle and transitory, and therefore may not be readily detectable in longer term studies that examine fasting blood samples.

Several techniques can be used to measure serum or plasma antioxidant capacity [34–36]. Five of the most common methods are whole serum susceptibility to conjugated diene formation (whole serum oxidation), plasma LDL oxidation susceptibility (LDL oxidation), ferric-reducing ability of plasma (FRAP), oxygen radical absorbance capacity (ORAC) and perchloric-acid-treated oxygen radical absorbance capacity (PCA-ORAC) [35]. To our knowledge, a study that compares all five methods has not been conducted; however, FRAP and ORAC assays have been shown to be weakly correlated in some conditions [35]. The objective of the current investigation was to determine whether acute antioxidant protection is imparted by soy protein with and without isoflavones in a healthy, free-living population and to determine whether correlations exist between five different methods of ex vivo antioxidant capacity assessment in this setting. The hypothesis was that consumption of soy protein would promote greater acute antioxidant capacity than control protein, and that soy containing isoflavones would have the greatest effect.

2. Materials and methods

2.1. Participants

Twenty healthy nonsmoking (4 male and 16 female) adults were recruited from the University of California at Davis to participate in this study. The University of California at Davis Institutional Review Board approved the human subjects protocol, and written informed consent was obtained from all participants in compliance with the Helsinki Declaration, as revised in 1983. Participants were excluded if they had a history of chronic disease, consumed a diet significantly high in isoflavones/polyphenols or took multivitamins daily.

2.2. Study design

Participants were assigned to one of three randomization schemes in this double-blind cross-over design experiment such that each subject underwent all three treatments, each separated by a 1-week washout period. The dietary treatments consisted of: (a) soy with isoflavones (Soy+): isolated soy protein with 110 mg of total aglycone isoflavones; (b) soy with trace isoflavones (Soy−): ethanol-washed isolated soy protein with <4 mg of total aglycone isoflavones; and (c) total milk protein (TMP): casein with 0 mg of isoflavones as control. The randomization schemes were as follows:

(1) Soy+ Soy− TMP
(2) Soy− TMP Soy+
(3) TMP Soy− Soy−

To minimize the possible confounding effects of diet, participants were asked to refrain from consuming soy products for 1 month prior to the study and to consume a diet that was low in flavonoids 24 h before each experimental day. Twenty-four-hour food records were collected to ensure compliance with dietary restrictions. Completed forms were analyzed using NUTRITIONIST V software, version 2 (First Data Bank, San Bruno, CA, USA).

Blood samples were collected in heparin, EDTA and serum tubes at four time points. The first blood draw, or baseline measurement, occurred at approximately 0800 h after a 12-h fast. Subsequently, each subject was asked to consume one of three isocaloric shakes containing 25 g of protein (Solae Co., St. Louis, MO, USA) and flavonoid-free ingredients such as ice cream, rice milk and strawberry syrup (550 kcal, 28.6 g of protein, 12 g of fat and 85.6 g of carbohydrate).

Blood was collected again at 4, 6 and 8 h after shake consumption to capture the peak appearance of isoflavones in the serum [37–39]. After a 4-h blood draw, lunch and water (ad libitum) were provided. This lunch (lean meat and cheese sandwich on white bread; no vegetables or fruits) provided approximately 550 cal and was low in fats, antioxidants and flavonoids. Subjects consumed no other food during the 8-h study period. Immediately after collection, blood samples were spun, aliquoted and stored at −80°C pending further analysis.

2.3. Experimental procedures

2.3.1. Analysis of serum isoflavone content

Analysis of soy isoflavones in serum was carried out according to the methods of Cimino et al. [40]. Total
aglycones of genistein and diadzein were extracted and measured directly on liquid chromatography–mass spectrometry (LC-MS) following enzymatic deconjugation of conjugated isoflavones. Samples (100 μl) were incubated with a mixture of sulfatase and glucuronidase (Sulfatase H-5; 100 U) for 3 h to obtain the total isoflavone concentration. Serum was extracted twice with 5 ml of hexane to remove the lipids and thrice with 5 ml of diethyl ether, and the organic phase was removed and evaporated to dryness at 50°C under nitrogen. Dried extracts were reconstituted in 0.5 ml of 50% methanol/water containing a known amount of biochanin A and analyzed by LC-MS to determine isoflavone concentrations.

For LC-MS, the extracted samples (100 μl) were injected onto a Discovery RP amide C18 column (25 cm×4.6 mm, 5 μm particle size; Supelco, Bellefonte, PA, USA), and isoflavones were eluted with a mobile phase of Solvent A (25% methanol containing 10 mM ammonium acetate and 71 mM triethylamine, pH 4.5) and Solvent B (95% methanol containing 10 mM ammonium acetate and 71 mM triethylamine, pH 5.5) at a flow rate of 1.0 ml/min. Isoflavones were separated using a linear gradient from 45% Solvent B to 65% Solvent B over an 11-min time period. The proportion of Solvent B increased linearly from 65% to 95% over 5 min and was held for another 5 min before returning to initial conditions. The column was equilibrated for 6.5 min prior to any subsequent sample injection. Isoflavones were detected using a PE Sciex API 100 Mass Spectrometer using negative ion monitoring of single ions using a heated nebulizer atmospheric pressure–chemical ionization interface. Isoflavone concentrations were expressed as micromoles per liter in serum after normalization with biochanin A. Intra-assay and interassay coefficients of variation were 5.8% and 10.8%, respectively. The detection limit was 0.8 pmol of each isoflavone injected onto the column.

2.3.2. Serum fat-soluble antioxidant levels

Serum α-tocopherol, retinol, lutein/zeaxanthin, β-cryptoxanthin, lycopene, α-carotene and β-carotene levels were analyzed using the procedure of Sowell et al. [41]. Fat-soluble compounds were extracted from serum using hexane (Sigma Chemical Co., St. Louis, MO, USA). Aliquots were then dissolved in the mobile phase of 1:1 ethanol and acetonitrile and injected onto a C18 reverse-phase high-performance liquid chromatography column with detection at 300, 325 and 450 nm. Peaks were identified and quantified using serum markers of the National Institutes of Standards and Technology.

2.3.3. Plasma ascorbic acid

To determine the levels of ascorbic acid, 0.5 ml of heparinized plasma was added to 2.0 ml of metaphosphoric acid (6.0 g/100 ml) in an eppendorf tube, vortexed and centrifuged at 3000 rpm for 10 min. This initial treatment occurred within 1 h of blood collection. The supernatant was then removed and frozen at −80°C to await further analysis. Within 3 months of collection, samples were analyzed by treatment with a dinitrophenylhydrazine thio-urea copper sulfate reagent (Sigma Chemical Co.) and evaluated spectrophotometrically at 520 nm.

2.3.4. Whole plasma oxidation

The assay for whole plasma oxidation was adapted from the method of Schnitzer [42]. Heparinized plasma samples were diluted 200-fold with phosphate-buffered saline (pH 7.4) and placed into a quartz cuvette. After dilution, 10 μl of 50 μM copper sulfate was added to bring the solution to a 1-ml volume with a final copper concentration of 10 μmol/L. Subsequently, the formation of conjugated dienes was monitored at 234 nm with a 12-cell visible spectrophotometer (UV-1601; Shimadzu Scientific Instruments, Inc., Columbia, MD, USA) kept at 37°C. Data were collected continuously until conjugated diene formation had reached a plateau and had been graphed as time versus absorbance. Lag time to oxidation was calculated as the intersection between the lag phase and the propagation phase line equations.

2.3.5. LDL oxidation susceptibility

The assay for LDL oxidation was adapted from the method of Esterbauer et al. [43]. Briefly, LDL was isolated from EDTA plasma by sequential density microultracentrifugation according to the method of Brousseau et al. [44] and incubated overnight in dialysis tubing placed in a nitrogen-purged phosphate-buffered solution (pH 7.4) containing Chelex 100 (Bio-Rad, Richmond, CA, USA) to remove EDTA. On the following morning, 75 μg of apo B was quantified by a Lowry protein assay and placed in a quartz cuvette. Phosphate-buffered solution (pH 7.4) and copper sulfate were then added to the LDL to produce a 5-μM copper solution in a final volume of 1 ml. Subsequently, the formation of conjugated dienes was monitored at 234 nm. Lag time to oxidation was determined in the same manner as for the oxidation of whole plasma samples.

2.3.6. FRAP

The FRAP assay was carried out according to the method of Benzie and Strain [45], as modified, to run on an Analette Analyzer (Precisions Systems, Natick, MA, USA). The plasma was mixed with FRAP reagent, and the reaction was monitored at a wavelength of 593 nm.

2.3.7. ORAC and PCA-ORAC

The ORAC and PCA-ORAC methods assays were carried out using the procedure described by Cao et al. [36], which was later modified to be able to use fluorescein as a probe [34]. Perchloric acid was used to extract the non-protein fractions of heparinized plasma. For preparation of plasma nonprotein fraction, plasma was diluted with 0.5 mol/L PCA (1:1, vol/vol). The samples were then centrifuged at 3000×g for 10 min at 4°C, and the supernatants
were removed as plasma nonprotein fraction and diluted for the ORAC assay.

ORAC$_{FL}$ assay was carried out on a FLUOstar Galaxy plate reader, which was equipped with an incubator and two injection pumps. The temperature of the incubator was set to 37°C. Assay procedures were based on the modified ORAC$_{FL}$ method [34] using fluorescein as fluorescent probe. 2,2’-Azobis(2-amidino-propane) dihydrochloride (AAPH) was used as a peroxyl generator, and Trolox was used as a standard. Forty microliters of sample, blank and Trolox calibration solutions were transferred to 48-well microplates in duplicate based on a set layout. The plate reader was programmed to record the fluorescence of ORAC$_{FL}$ at every cycle. The number of running cycles for the complete ORAC$_{FL}$ analysis was set to 25, and the cycle time was automatically given by the instrument according to the number of wells used in the assay. Peroxyl-radical-induced oxidation started immediately after the addition of AAPH; thus, the third reading cycle can be considered as the starting point of the reaction. The final results were calculated by using the differences of areas under the fluorescent decay curve between the blank and the sample (expressed as µmol Trolox Eq/L).

2.4. Statistical analysis

Serum isoflavone, fat-soluble antioxidant and ascorbic acid levels, and diet components were compared across treatment days using repeated-measures analysis of variance (ANOVA) with a significance level of $P \leq 0.05$ and using Tukey’s honestly significant difference post hoc analysis to determine the differences between treatments over time. The effects of soy protein on measures of serum antioxidant capacity were also determined by ANOVA. Prior to ANOVA, it was determined that there was no interaction between treatment and time. Baseline, 4-h, 6-h and 8-h values were compared for each of the participants across the three test meals. Finally, Pearson’s bivariate correlation coefficients were calculated to compare the five serum antioxidant capacity measurements across all three treatments at each time point. These statistical analyses were performed using SPSS 10.0 for Windows.

3. Results

Sixteen of the original 20 subjects completed the intervention. Three women and one man were removed prior to study completion due to inability to comply with the protocol. Initial repeated-measures ANOVA of baseline serum isoflavone levels revealed a statistical outlier, suggesting that this participant was also noncompliant. This subject was therefore removed from the data set, and data from 15 participants were included in the final analysis. No treatment order effect was observed for the data. Dietary analysis (data not shown) revealed no significant differences in the intake of total kilocalories, macronutrients or antioxidant-related micronutrients of the participants between treatment days.

A significant increase ($P \leq 0.05$) in serum levels of the isoflavones genistein and daidzein was observed in response to Soy$^+$ treatment (Table 1), reaching an average of 18.9±34.7 and 9.8±16.0 ng/100 µl serum, respectively, at the 8-h time point, as expected based on study design. Baseline serum levels of the antioxidants α-tocopherol, retinol, lutein/zeaxanthin, β-cryptoxanthin, lycopene, α-carotene, β-carotene and ascorbic acid did not differ significantly between treatment days (Table 2).

The antioxidant capacity of serum after consumption of protein treatments was assessed by five different methods. There were no significant differences between treatments using the whole serum, LDL oxidation, ORAC or FRAP...
assay (Table 3). However, serum PCA-ORAC values increased significantly over time in response to Soy/C0 treatment, in comparison to TMP treatment (Table 3) \((P=.03)\).

Correlation analysis was used to compare the five measurements of serum antioxidant capacity. The whole serum/FRAP and ORAC/PCA-ORAC assays were the only pairs of assays to be correlated across all four time points (Table 3).

### 4. Discussion

Epidemiological and clinical trials suggest that regular consumption of soy is associated with favorable cardio-

### Table 3

**Antioxidant capacity values**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Baseline</th>
<th>4 h</th>
<th>6 h</th>
<th>8 h</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Whole plasma oxidation susceptibility (lag time in min)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soy(^+)</td>
<td>131 (53)</td>
<td>128 (53)</td>
<td>140 (55)</td>
<td>145 (56)</td>
</tr>
<tr>
<td>Soy(^-)</td>
<td>140 (60)</td>
<td>142 (57)</td>
<td>149 (60)</td>
<td>153 (59)</td>
</tr>
<tr>
<td>TMP</td>
<td>130 (59)</td>
<td>118 (54)</td>
<td>131 (54)</td>
<td>139 (53)</td>
</tr>
<tr>
<td><strong>LDL oxidation susceptibility (lag time in min)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soy(^+)</td>
<td>54 (22)</td>
<td>56 (24)</td>
<td>51 (17)</td>
<td>49 (15)</td>
</tr>
<tr>
<td>Soy(^-)</td>
<td>50 (17)</td>
<td>51 (12)</td>
<td>47 (17)</td>
<td>51 (18)</td>
</tr>
<tr>
<td>TMP</td>
<td>51 (17)</td>
<td>57 (27)</td>
<td>55 (17)</td>
<td>49 (12)</td>
</tr>
<tr>
<td><strong>FRAP (µmol Trolox Eq/L)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soy(^+)</td>
<td>207 (32)</td>
<td>200 (31)</td>
<td>198 (31)</td>
<td>190 (30)</td>
</tr>
<tr>
<td>Soy(^-)</td>
<td>209 (35)</td>
<td>206 (35)</td>
<td>203 (33)</td>
<td>195 (31)</td>
</tr>
<tr>
<td>TMP</td>
<td>206 (37)</td>
<td>192 (33)</td>
<td>190 (33)</td>
<td>184 (33)</td>
</tr>
<tr>
<td><strong>ORAC (µmol Trolox Eq/L)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soy(^+)</td>
<td>14,415 (1144)</td>
<td>15,206 (2186)</td>
<td>15,824 (1449)</td>
<td>15,751 (1559)</td>
</tr>
<tr>
<td>Soy(^-)</td>
<td>14,406 (1224)</td>
<td>14,927 (3225)</td>
<td>16,129 (1561)</td>
<td>16,156 (1754)</td>
</tr>
<tr>
<td>TMP</td>
<td>14,358 (847)</td>
<td>15,011 (1209)</td>
<td>15,287 (1054)</td>
<td>15,293 (1265)</td>
</tr>
<tr>
<td><strong>PCA-ORAC (µmol Trolox Eq/L)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soy(^+)</td>
<td>1116 (136)</td>
<td>1135 (136)</td>
<td>1312 (126)</td>
<td>1250 (163)</td>
</tr>
<tr>
<td>Soy(^-)</td>
<td>1170 (138)</td>
<td>1235 (191)</td>
<td>1352 (114)</td>
<td>1346 (129)*</td>
</tr>
<tr>
<td>TMP</td>
<td>1068 (127)</td>
<td>1153 (102)</td>
<td>1263 (118)</td>
<td>1148 (133)*</td>
</tr>
</tbody>
</table>

Mean (±S.D.) change in antioxidant capacity values. There were no significant differences over time among the three protein treatments using whole plasma, LDL oxidation, FRAP or ORAC assay. PCA-ORAC was significantly \((P=.03)\) different for Soy/C0 treatment compared to TMP treatment across the 8-h time period.

* Significance \((P<.05)\) was determined by three-factor repeated-measures ANOVA with interaction term and Tukey–Kramer post hoc test.

### Table 4

**Correlation between antioxidant capacity values**

<table>
<thead>
<tr>
<th>Baseline</th>
<th>4 h</th>
<th>6 h</th>
<th>8 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole plasma</td>
<td>LDL oxidation</td>
<td>FRAP</td>
<td>ORAC</td>
</tr>
<tr>
<td>Whole plasma</td>
<td>1.0</td>
<td>0.1</td>
<td>0.3*</td>
</tr>
<tr>
<td>LDL oxidation</td>
<td>0.1</td>
<td>1.0</td>
<td>0.1</td>
</tr>
<tr>
<td>FRAP</td>
<td>0.3*</td>
<td>0.1</td>
<td>1.0</td>
</tr>
<tr>
<td>ORAC</td>
<td>0.3*</td>
<td>0.1</td>
<td>0.2</td>
</tr>
<tr>
<td>PCA-ORAC</td>
<td>0.3*</td>
<td>0.3**</td>
<td>0.1</td>
</tr>
</tbody>
</table>

Correlation coefficients for antioxidant values. Pearson’s bivariate correlation coefficients were calculated to compare the five oxidation measurements. Of the five methods, the whole plasma/FRAP and ORAC/PCA-ORAC assays were the only pairs of assays to be correlated across all four time points (Table 4).

* \(P<.05\). ** \(P<.01\).
vascular risk factors, but the strength of these associations, their biologic mechanisms and their clinical significance remain somewhat controversial [6,46,47]. One potential mechanism behind cardioprotective effects is that soy imparts antioxidant protection; however, clinical trials investigating this hypothesis have yielded conflicting results [8,14,26–29]. To further explore the antioxidant theory, in the current study, the acute postprandial antioxidant protection imparted after the consumption of 25 g of soy protein, with or without isoflavones, was investigated in a cohort of healthy adults.

The results from our investigation suggest that consumption of soy protein, with or without isoflavones, results in only a very modest increase in postprandial antioxidant capacity. Statistically significant increases in plasma antioxidant capacity in comparison to the control TMP treatment were observed after participants have consumed Soy™ treatment using the PCA-ORAC assay. No other statistically significant changes were observed in antioxidant capacity, as assessed by a variety of methods. Other dietary antioxidants, such as ascorbic acid and fat-soluble vitamins, were not particularly high in this population based on exclusion criteria, dietary records and serum levels. Therefore, this was not felt to be a confounding factor in the results obtained. Additionally, the low antioxidant and flavonoid content of the lunch was not anticipated to substantially affect serum antioxidant concentrations. It is acknowledged, however, that there is no information in the literature regarding the effects of subsequent meals on isoflavone enterohepatic circulation or isoflavone kinetics within the 8-h postprandial period that we examined. Therefore, the possibility that the lunch affected the results cannot be excluded.

These findings are consistent with work completed by other research groups that investigated the effects of chronic soy consumption on antioxidant status in vivo [14,28–30]. When consumed in physiologic amounts by free-living populations, consisting of both hypercholesterolemic and normocholesterolemic individuals, soy protein appears to have modest to no effects on acute and chronic plasma antioxidant capacity. In the current study, the only significant effect was observed with Soy™ (rather than with Soy”) preparations, indicating little contribution of isoflavones to the overall antioxidant effect. This is further supported by research failing to detect increased lag time to LDL oxidation after supplementation with isoflavone extracts [48,49]. Furthermore, in vitro work has demonstrated that high concentrations of isoflavones (levels unachievable through diet) must be reached for peroxidation inhibition to occur [15].

It has been suggested that methods for accurately measuring the total antioxidant capacity of plasma after consumption of soy protein or other polyphenol-rich foods have yet to be developed [50] or are not sufficiently sensitive or selective [51]. This may explain why significant antioxidant protection was only observed through the PCA-ORAC assay. Although correlations were observed between the whole plasma/FRAP assays (both use metal to induce oxidation in a relatively unprocessed blood sample, which still contains aqueous components contributing to antioxidant capacity) and the ORAC/PCA-ORAC assays (which only differ in the use of PCA to treat the sample), the lack of correlation between all five measurements of serum antioxidant capacity establishes that each method is distinct. It is not surprising that the susceptibility of isolated LDL to oxidation was not modified by the previous soy-containing meal, since insignificant amounts of isoflavones are carried via these lipoproteins. Indeed, the five methods evaluate antioxidant capacity in differing systems (i.e., aqueous whole plasma vs. isolated lipoproteins vs. small molecules). Additionally, ORAC and PCA-ORAC use AAPH as a peroxyl radical generator, whereas other methods use metal ions (either copper or iron) to induce oxidation. These differences contribute to the inherent difficulties of making statistical and biologic comparisons in the field of antioxidant research. Of the five assays used, the PCA-ORAC method is unique in that it measures the activity of low-molecular-weight antioxidants [52]. In this technique, plasma is pretreated with perchloric acid before analysis so that a protein-free fraction can be obtained. Albumin, which makes a major contribution to plasma antioxidant capacity, is removed from the sample, and subtle changes in antioxidant activity are detected. To our knowledge, this is the first investigation to use the PCA-ORAC assay to measure the antioxidant capacity of human plasma following a soy protein meal.

Alternatively, isoflavonoids may not impact in vivo antioxidant capacity since, in the plasma and urine of humans, over 75% of genistein and diadzein exist in conjugated form as glucuronide or sulfate [40,53]. Genistein and diadzein have only one hydroxyl group on the B-ring and thus have a lower antioxidant capacity compared to other flavones such as quercetin or myricetin, which have two hydroxyl groups on the B-ring [54]. Conjugation with sulfate or glucuronide occurs on these hydroxyl groups; thus, conjugation decreases the antioxidant capacity of the isoflavonoid metabolite. Conjugation can occur on more than one of the hydroxyl groups, and mixed conjugates of sulfate and glucuronide may also occur, all of which would even further lower any measured antioxidant capacity of isoflavonoid metabolites.

Compared to other flavonoids, the quantities of isoflavonoids that are apparently absorbed are much larger, since up to 30% of the amounts consumed appear in the urine [55]. This absorption will not likely be a limitation in altering in vivo antioxidant capacity. The combination of lower antioxidant capacity and extensive conjugation more likely accounts for lack of response following a soy meal.

In conclusion, consumption of soy protein was not associated with a significant increase in acute postprandial antioxidant capacity in four of five assay methods. Any
observed and putative in vivo health effects of soy consumption are likely derived through mechanisms other than direct antioxidant protection.

Acknowledgment

Protein products were provided by Solae Co.

References


[38] Setchell KDR. Absorption and metabolism of soy isoflavones — from food to dietary supplements and adults to infants. J Nutr 2000;130:654S–655S.


